Researchers Database
SODA SAYO
Affiliation： Department of Pulmonary Medicine and Clinical Immunology | |||
Last Updated :2026/04/21
Research achievements
Published Papers
- 2018, 5708239, Apr. 2018
- 2(1), 49-58, Jan. 2012
- 間質性肺炎患者における筋炎関連自己抗体の陽性率と治療反応性及び予後についての検討., 森田弘子, 伊藤紘, 清水悠佳, 正和明哲, 中村祐介, 小池亮介, 奥冨泰明, 渡邊泰治, 横山達也, 曾田紗世, 塩原太一, 池田直哉, 新井良, 知花和行, 武政聡浩, 倉沢和宏, 清水泰生, DJMS, 47, 105, 2020
- Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma., Kishikawa T, Kasai T, Okada M, Nakachi I, Soda S, Arai R, Takigami A, Sata M, Thorac Cancer, 11(4), 935-942, Feb. 2020
- Auto-antibody evaluation in idiopathic interstitial pneumonia and worse survival of patients with Ro52/TRIM21auto-antibody., Morita H, Shimizu Y, Nakamura Y, Okutomi H, Watanabe T, Yokoyama T, Soda S, Ikeda N, Shiobara T, Miyoshi M, Chibana K, Takemasa A, Kurasawa K, J Clin Biochem Nutr, 67(2), 199-205, Sep. 2020
- A case of spindle cell dominant histiocytic sarcoma showing a complete remission after first-line chemotherapy with doxorubicin and ifosfamide., Nakamura Y, Takemasa A, Kushima Y, Soda S, Ikeda N, Arai R, Chibana K, Nakazato Y, Yokose T, Shimizu Y, Niho S, J Chemother, 20, 1-6, Nov. 2020
Original paper
- Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma., Kishikawa Takayuki;Kasai Takashi;Okada Masahiko;Nakachi Ichiro;Soda Sayo;Arai Ryo;Takigami Ayako;Sata Masafumi, Thoracic cancer, 11(4), 935-942, 2020
- Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma., Kishikawa Takayuki;Kasai Takashi;Okada Masahiko;Nakachi Ichiro;Soda Sayo;Arai Ryo;Takigami Ayako;Sata Masafumi, Thoracic cancer, 11(4), 935-942, 2020
- Auto-antibody evaluation in idiopathic interstitial pneumonia and worse survival of patients with Ro52/TRIM21auto-antibody., Morita Hiroko;Shimizu Yasuo;Nakamura Yusuke;Okutomi Hiroaki;Watanabe Taiji;Yokoyama Tatsuya;Soda Sayo;Ikeda Naoya;Shiobara Taichi;Miyoshi Masaaki;Chibana Kazuyuki;Takemasa Akihiro;Kurasawa Kazuhiro, Journal of clinical biochemistry and nutrition, 67(2), 199-205, Sep. 2020
- Auto-antibody evaluation in idiopathic interstitial pneumonia and worse survival of patients with Ro52/TRIM21auto-antibody., Morita Hiroko;Shimizu Yasuo;Nakamura Yusuke;Okutomi Hiroaki;Watanabe Taiji;Yokoyama Tatsuya;Soda Sayo;Ikeda Naoya;Shiobara Taichi;Miyoshi Masaaki;Chibana Kazuyuki;Takemasa Akihiro;Kurasawa Kazuhiro, Journal of clinical biochemistry and nutrition, 67(2), 199-205, Sep. 2020
- Changing patterns of pulmonary abnormalities in rheumatoid arthritis., Tanaka Ayae;Kurasawa Kazuhiro;Soda Sayo;Takamura Yuta;Miyao Tomoyuki;Hasegawa Anna;Hiyama Tomoka;Yamazaki Ryutaro;Arai Satoko;Owada Takayoshi;Arima Masafumi;Arakawa Hiroaki;Maezawa Reika, Respiratory investigation, 61(1), 27-39, 04 Oct. 2022
- Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study., Ikeda Naoya;Arai Ryo;Soda Sayo;Inoue Takashi;Uchida Nobuhiko;Nakamura Yusuke;Masawa Meitetsu;Kushima Yoshitomo;Okutomi Hiroaki;Takemasa Akihiro;Shimizu Yasuo;Niho Seiji, Thoracic cancer, 13(9), 1342-1348, 22 Mar. 2022
- Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study., Mimori Tomoyasu;Shukuya Takehito;Ko Ryo;Okuma Yusuke;Koizumi Tomonobu;Imai Hisao;Takiguchi Yuichi;Miyauchi Eisaku;Kagamu Hiroshi;Sugiyama Tomohide;Azuma Keisuke;Namba Yukiko;Yamasaki Masahiro;Tanaka Hisashi;Takashima Yuta;Soda Sayo;Ishimoto Osamu;Koyama Nobuyuki;Kobayashi Kunihiko;Takahashi Kazuhisa, Cancers, 14(2), 11 Jan. 2022
- Transcutaneous gas monitoring is a useful tool to detect respiratory depression during bronchoscopy performed under propofol sedation., Yazawa Nana;Nakamura Yusuke;Takemasa Akihiro;Uchida Nobuhiko;Kushima Yoshitomo;Masawa Meitetsu;Okutomi Hiroaki;Soda Sayo;Ikeda Naoya;Arai Ryo;Chibana Kazuyuki;Niho Seiji;Shimizu Yasuo, Respiratory investigation, 61(6), 793-799, 27 Sep. 2023
- Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)., Nishioka Naoya;Imai Hisao;Endo Masahiro;Notsu Akifumi;Doshita Kosei;Igawa Satoshi;Yokouchi Hiroshi;Ninomiya Takashi;Tokito Takaaki;Soda Sayo;Fujiwara Takasato;Asao Tetsuhiko;Nakamichi Shinji;Kawamura Takahisa;Inomata Minehiko;Nakashima Kazuhisa;Ito Kentaro;Goto Yasuhiro;Umeda Yukihiro;Hirai Soichi;Ushio Ryota;Yokoo Keiki;Takeda Takayuki;Fukui Tomoya;Ishihara Masashi;Osaki Takashi;Kubo Sousuke;Fujiwara Takumi;Yamamoto Chie;Tsuda Takeshi;Tamura Nobumasa;Hosokawa Shinobu;Chihara Yusuke;Ikeda Satoshi;Furuya Naoki;Nakahara Yoshiro;Miura Satoru;Okamoto Hiroaki, Targeted oncology, 19(3), 423-433, 13 Apr. 2024
- Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060., Tozuka Takehiro;Minegishi Yuji;Yamaguchi Ou;Watanabe Kana;Toi Yukihiro;Saito Ryota;Nagai Yoshiaki;Tamura Yosuke;Shoji Tetsuaki;Odagiri Haruka;Ebi Noriyuki;Sakai Kosuke;Kanaji Nobuhiro;Izumi Makoto;Soda Sayo;Watanabe Satoshi;Morita Satoshi;Kobayashi Kunihiko;Seike Masahiro, JTO clinical and research reports, 5(4), 100655, 20 Feb. 2024
- Corrigendum to "Transcutaneous gas monitoring is a useful tool to detect respiratory depression during bronchoscopy performed under propofol sedation" [Resp. Invest. 61 (2023) 793-799]., Yazawa Nana;Nakamura Yusuke;Takemasa Akihiro;Uchida Nobuhiko;Kushima Yoshitomo;Masawa Meitetsu;Okutomi Hiroaki;Soda Sayo;Ikeda Naoya;Arai Ryo;Chibana Kazuyuki;Niho Seiji;Shimizu Yasuo, Respiratory investigation, 62(2), 295, 30 Jan. 2024
- Dysregulated metabolic pathways of pulmonary fibrosis and the lipids associated with the effects of nintedanib therapy., Shimizu Yasuo;Horibata Yasuhiro;Domae Mariko;Nakamura Yusuke;Yokoyama Tatsuya;Arai Ryo;Shiobara Taichi;Takemasa Akihiro;Koike Ryosuke;Uchida Nobuhiko;Masawa Meitetsu;Tei Rinna;Watanabe Taiji;Morita Hiroko;Miyoshi Masaaki;Soda Sayo;Niho Seiji;Igami Ko;Sugimoto Hiroyuki, Respiratory research, 26(1), 166, 28 Apr. 2025
- Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib., Hirokawa Hisanori;Hirata Hirokuni;Azuma Hayase;Sugitate Kei;Soda Sayo;Matsushima Jun;Fukushima Yasutsugu, Respiratory medicine case reports, 51, 102094, 22 Aug. 2024
Unclear